R&D In Brief: Lilly’s Cyramza Cleared In Lung, SABCS & ASH Updates
Lilly adds significant new market for ramucirumab, while early data presented at San Antonio Breast Cancer Symposium and American Society of Hematology annual meeting pave the way for future filings.
You may also be interested in...
Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?
I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.